3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
2
Terminated
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Carcinoma, Hepatocellular
9
Esophageal Neoplasms
7
Stomach Neoplasms
4
Small Cell Lung Carcinoma
4
Rectal Neoplasms
4
Nasopharyngeal Carcinoma
4
Colorectal Neoplasms
4
Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Colonic Neoplasms
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Hodgkin Disease
2
Glioblastoma
2
mCRPC
1
Uterine Cervical Neoplasms
1
Unresectable Stage III Non-small Cell Lung Cancer
1
Tongue Squamous Cell Carcinoma
1
SCLC, Extensive Stage
1
Rare Tumour
1
Non-Muscle Invasive Bladder Neoplasms
1
Non Squamous Non-small Cell Lung Cancer
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
NSCLC
1
MSI-H Colorectal Cancer
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Interventions
selinexor
3
pegaspargase
3
Oxaliplatin
2
Gemcitabine
2
tislelizumab
1
sugemalimab
1
Thiotepa
1
Radiotherapy
1
Immune Checkpoint Inhibitors
1
Azacitidine
1
Asparaginase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Lymphoma, Extranodal NK-T-Cell
×
tislelizumab
×
Clear all
NCT07502768
2026-03-31
EpiRev-NKT
Fudan University
Phase 1/2
Not yet recruiting
107 enrolled